Drug intelligence / Profile preview

HSV formulation 2 with adjuvant 2

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**HSV formulation 2 with adjuvant 2** is an investigational intramuscular herpes simplex virus-targeted immunotherapy vaccine formulation evaluated by GSK in the Phase I/II TH HSV REC-003 study. It was one of several exploratory HSV vaccine formulations tested in healthy adults, consisting of an undisclosed HSV antigen formulation paired with an undisclosed adjuvant. The broader GSK3943104 therapeutic HSV vaccine program was studied for recurrent genital herpes, but did not meet its Phase II primary efficacy objective and was not advanced to Phase III.

Beyond the preview

Go deeper on HSV formulation 2 with adjuvant 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HSV formulation 2 with adjuvant 2.

Explore the full profile